Results 1 to 10 of about 13,031 (154)

PCSK9 Inhibitors: The Evolving Future [PDF]

Health Science Reports
Introduction PCSK9 inhibitors are a novel class of medications that lower LDL cholesterol (LDL‐C) by increasing LDL receptor activity, promoting clearance of LDL‐C from the bloodstream.
Bijay Mukesh Jeswani, Shubhangi Sharma, Sawai Singh Rathore, Abubakar Nazir, Rohit Bhatheja, Kapil Kapoor   +5 more
doaj   +3 more sources

A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022

Frontiers in Endocrinology, 2023
BackgroundSince the approval of the proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for marketing in 2015, PCSK9 inhibitors have attracted significant interest in the field of cardiovascular endocrinology.
Qin Luo, Qin Luo, Zhenchu Tang, Zhenchu Tang, Panyun Wu, Panyun Wu, Zhangling Chen, Zhangling Chen, Zhenfei Fang, Zhenfei Fang, Fei Luo, Fei Luo   +11 more
doaj   +3 more sources

Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a promising class of lipid‐lowering therapy, although their use has been limited by cost concerns.
Elias J. Dayoub, Lauren A. Eberly, Ashwin S. Nathan, Sameed Ahmed M. Khatana, Srinath Adusumalli, Ann Marie Navar, Jay Giri, Peter W. Groeneveld   +7 more
doaj   +3 more sources

Integrating pharmacovigilance signals with real-world validation: a study on neurological events associated with PCSK9 inhibitors [PDF]

Frontiers in Medicine
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs widely used in clinical practice for the treatment of dyslipidemia.
Bing Zhu, Qiqi Shao, Jun Cui, Zhenyan Fu, Yitong Ma   +4 more
doaj   +2 more sources

Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials [PDF]

American Journal of Preventive Cardiology
Background: Injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an established strategy to lower low-density lipoprotein cholesterol (LDL-C) and reduce atherosclerotic cardiovascular disease risk. Recently developed oral PCSK9
Aditya Karthikeyan, Avrohom Karp, Maisha Maliha, Amrin Kharawala, Sridhar Mangalesh, Priyansh Shah, Vishakha Modak, Adir Alper, Apoorva Doshi, Hamsa Murli, Vikyath Satish, Kuan-Yu Chi, Robert T. Faillace   +12 more
doaj   +2 more sources

Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis [PDF]

International Journal of Cardiology. Cardiovascular Risk and Prevention
Background: Peripheral artery disease (PAD) reflects systemic atherosclerosis driven by dyslipidemia, particularly elevated LDL-C. Despite first-line statin therapy, many patients fail to reach lipid targets or are intolerant, necessitating alternatives.
Khadeeja Ali Hamzah, Yousif Hameed Kurmasha, Mohamed Fouad Abdrabo, Mohamed F. Srour, Ali Saad Al-Shammari, Mohammed Hamed Ibrahium Badi, Mohammedsadeq A. Shweliya, Nihar Jena, Yasar Sattar   +8 more
doaj   +2 more sources

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

Frontiers in Cardiovascular Medicine, 2023
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are ...
Hongzhen Chen, Xiaomin Chen
doaj   +1 more source

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance

Безопасность и риск фармакотерапии, 2023
Scientific relevance. The main cause of cardiovascular pathologies is atherosclerosis, which is secondary to lipid metabolism disorders, in particular, the accumulation of low-density lipoprotein (LDL) cholesterol.
K. O. Shnaider, M. L. Maximov, V. A. Baranova, A. A. Nekipelova   +3 more
doaj   +1 more source

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System

Cardiovascular Therapeutics, 2022
Background. Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). Objective.
Lingqing Ding, Congqin Chen, Yongkuan Yang, Jie Fang, Longxing Cao, Yige Liu   +5 more
doaj   +1 more source

Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center

Journal of the Formosan Medical Association, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, are currently approved for clinical use by Taiwan National Health Insurance (NHI) in patients who had a recent atherosclerotic cardiovascular disease with ...
Chia-Ling Tsai, Ya-Hui Chang, Cheng-Huang Su, Yih-Jer Wu, Hung-I Yeh, Chao-Feng Lin   +5 more
doaj   +1 more source